"Johnson & Johnson on Tuesday raised its 2025 sales forecast after reporting quarterly earnings that topped Wall Street expectations, and announced plans to spin off its orthopedics business into a standalone company. The healthcare conglomerate now expects product revenue of $93.5 billion to $93.9 billion, about $300 million higher than its prior forecast and above analysts' expectations of $93.4 billion, according to LSEG data."
"The company said it planned to focus on high-growth, high-margin areas as part of its separation plans, such as oncology, immunology, neuroscience, surgery, vision care, and cardiovascular. J&J Chief Financial Officer Joe Wolk said the company was exploring multiple paths for the separation, with a primary focus on a tax-free spin-off, but remained open to other options."
Johnson & Johnson raised its 2025 product revenue forecast to $93.5 billion–$93.9 billion, about $300 million above its prior forecast and slightly above analysts' expectations. The company plans to separate its orthopedics business into a standalone firm named DePuy Synthes within 18 to 24 months. The orthopedics unit generated around $9.2 billion last year, roughly 10% of total revenue. J&J began a two-year restructuring of orthopedics in 2023 that included exiting certain markets and stopping some products. The company will concentrate on high-growth, high-margin areas and is exploring a tax-free spin-off among other options.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]